Business Context and Reporting Period
This Form 8-K is a current report filed by ChromaDex Corporation (not Niagen Bioscience, Inc.) on March 28, 2017, covering events occurring on March 27, 2017. The filing reports the appointment of a new director to the Company's Board of Directors.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on corporate governance changes and associated compensation arrangements.
Material Changes
The primary material change reported is the appointment of Steven D. Rubin to the Board of Directors and the Nominating and Corporate Governance Committee. No financial or operational changes were reported in this document.
Management Commentary and Compensation Details
- Appointment: Steven D. Rubin was appointed to the Board on March 27, 2017.
- Equity Compensation: Mr. Rubin received an initial grant of a nonstatutory stock option to purchase 40,000 shares of common stock, vesting in three equal annual installments.
- Cash Compensation: Mr. Rubin is entitled to a $30,000 annual cash retainer for board service and a $5,000 annual cash retainer for committee service.
- Future Eligibility: He is eligible for additional equity compensation in the future and will enter into the Company's standard indemnification agreement.
Investor Verification Checklist
- Verify the identity and background of the newly appointed director, Steven D. Rubin.
- Confirm the vesting schedule and exercise price of the 40,000 stock options granted.
- Review the Company's non-employee director compensation policy to understand the standard for future grants.
- Check for any potential conflicts of interest or related party transactions involving Mr. Rubin (the filing states none are currently known).